BCL7C

Across TCGA pan-cancer cohorts, BCL7C Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BCL7C data layer compared with 22 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher BCL7C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCL7C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, ESCA, and LIHC are the cancer types where BCL7C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	12	view →
ESCA	DFS	Median	II,III,IV	0.152	0.525	.004	12	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
UCEC	OS	Median	All	1.000	0.654	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BCL7C–DLBC (DFS)

Open the DLBC breakdown →